Articles On Botanix Pharmaceuticals (ASX:BOT)

The S&P/ASX 200 Index (ASX: XJO) is starting the week on a positive note. At the time of writing, the benchmark index is up 0.35% to 8,260.2 points. Four ASX shares that have failed to follow the market higher today are listed below. H...

ASX edges up as Trump de-escalates China tariffs Copper jumps on Peru mine drama ResMed soars, GDG sinks, oil slips   The ASX had a bit of a spring in its step on the last trading day of the week, leaping higher by 0.6% as the mining big...

Highlights: Short interest remained elevated in uranium and lithium names, with some companies experiencing mild increases over the past week. Lifestyle Communities gained further short interest momentum following previous underp...

Global drug companies again are on the alert after Donald Trump reiterated his intention to impose a pharma tariff rumoured to be 25% No sweat! as Botanix raises $40 million in a placement Imricor’s ablation news lauded as a “truly groundb...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin ASX200 futures are pointing to a positive start, up 18 points, but US markets finish...

The All Ordinaries Index (ASX: XAO) is up 0.6% in morning trade, with this ASX All Ords healthcare share charging ahead of those gains. The outperforming stock in question is clinical dermatology company Botanix Pharmaceuticals Ltd (ASX: B...

Highlights: Several companies within the Australian market exhibit strong executive participation, reflecting confidence in their strategies. Businesses across various sectors, including resources, technology, and telecommunicati...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

ASX pharmaceutical companies are retaining their assets longer and advancing them to commercialisation LTR Pharma has established several commercialisation pathways for its novel nasal spray to treat erectile dysfunction  Botanix is indepe...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

ASX dips further amid tariff uncertainty Coal stocks fall after Macquarie downgrade Gold gains as ASX correction looms   The ASX saw fluctuations on Thursday, with early gains reversed in the afternoon as investor apprehension grew around...

Botanix elevated to S&P/ASX 300 index with share price more than doubling in past year Company’s Sofdra treatment for excessive underarm sweating approved by US FDA in June 2024 After a soft launch of Sofdra in the US, Botanix is rolli...

Stockhead’s Tylah Tully chats with  Botanix Pharmaceuticals (ASX:BOT) CEO Dr Howie McKibbon, to get the short end of the long story on the company’s latest news. Botanix has recently been included in the ASX 300, which is part of the compan...

Highlights: The ASX200 recorded a decline, with technology leading the losses, while utilities and energy showed resilience. Botanix Pharmaceuticals, Vulcan Energy Resources, and Vista Group International performed well amid the...

The ASX200 closed down 0.9% at 7,890 points. It was a bloodbath today and IT was the worst performing sector, down 3.9%, followed by Industrials, down 2%, and Health Care, down 1.8%. Utilities was the best performing sector, up 1.4%,...

Like London buses, takeovers tend to come in a rush Mayne Pharma had struggled for years, but its performance was improving Takeovers in the ASX biotech sector have been few and far between The ‘London’ Bus theory goes that if one takeove...

Highlights Company nears break-even amid intensified research and development Debt-free operations provide a strong foundation for financial stability Focus on dermatology and antimicrobial innovations drives its strategic direction...

S&P/ASX All Ords Index (ASX: XAO) shares closed higher on the first day of trading for 2025. The ASX All Ords finished 0.53% higher at 8,465 points on Thursday. Here are five ASX All Ords shares that started the new year on a pos...

With just five trading days ‘til Christmas, the ASX closed up 0.78% at 8,314 points. Bitcoin jumped to an all-time record high above $US107,000 after Donald Trump confirmed plans for a U.S. strategic reserve for the cryptocurrency. Th...

Immutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher revenue, despite ongoing NDIS delays Botanix dispatches its first US prescriptions for its anti-sweat remedy   The year is ending with a bang ra...

Botanix (ASX:BOT) has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating. According to Botanix, the first prescriptions were quickly followed up by the first delive...

Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil...

True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders approved the moniker change at Wednesday’s AGM. The new name “combines our focus on neuro-degenerative diseases with the...

Alive and Kicking is renowned biotech journo Tim Boreham’s new daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.   Botanix plans a US launch of its anti-sweating treatment in the...

Looking to add a few small-cap ASX healthcare stocks to your portfolio with some outsized growth potential? Considering that the small-cap sector's potential for outsized share price gains comes with added risks, we take a look at two ASX h...

ASX healthcare shares are often touted here on the Australian share market. We are home to some of the most innovative players in the healthcare domain. But there's also a handful of companies that are growing their business over in the...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

The ASX200 reversed its trend to end the week in the green, up 0.35% Nearly all sectors made gains, with Utilities up the most, by 1.9%. Discretionary dipped the most, down 0.4%, Materials and Industrials followed, both falling short, bu...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a small gain. At the time of writing, the benchmark index is up 0.1% to 7,777.4 points. Four ASX shares that are rising more than most today are lis...

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are ending the week on a positive note. In morning trade, the clinical dermatology company's shares are up 9% to a 52-week high of 36.5 cents. Why are Botanix Pharmaceuticals shares rising? Inve...

It’s looking like another red day on the market, with the ASX flattish around intraday trades. Sector performance is mixed, with healthcare leading the decline at 0.7%, followed closely by IT which is down half a percent. Today repres...

Botanix Pharmaceuticals (ASX:BOT) on Thursday described itself as having transitioned from a development stage to being revenue-generating dermatology company, following FDA approval for its product Sofdra. Sofdra – sofpironium gel – has...

Control Bionics’s shares surge after TGA approval Control Bionics (ASX:CBL) surged by 51% this morning after announcing a TGA approval for its DROVE autonomous wheelchair module. DROVE has now been officially classified as a Class 1 Medical...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price will be one to watch closely this week. That's because the clinical dermatology company has just announced some very big news.. Why is the Botanix Pharmaceuticals share price on watch?...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced that the US FDA has approved  Sofdra (sofpironium).

ASX closes lower, but Energy sector blinks green Uranium mining stocks surged on Peter Dutton’s nuclear plans VanEck to launch Australia’s first Bitcoin ETF tomorrow    Local shares closed Wednesday -0.1% lower as gains in Energy were of...

The All Ordinaries Index (ASX: XAO) is up 0.1% in morning trade today, but this ASX All Ords stock isn't going anywhere just yet. Shares in the clinical dermatology company closed at 34 cents apiece yesterday, which sees the stock up a...

FDA panel rejects MDMA for PTSD treatment, citing safety and data concerns Advocates argue MDMA’s benefits outweigh risks, call for further research. South Africa legalises personal cannabis use, setting precedent for African nations    G...

The S&P/ASX 200 Index (ASX: XJO) is having another disappointing session. In afternoon trade, the benchmark index is down 0.65% to 7,705.1 points. Four ASX shares that are not letting that hold them back are listed below. Here's why t...

Clinical dermatology company, Botanix Pharmaceuticals (ASX:BOT) has submitted the last label materials to the US Food & Drug Administration (FDA) for the approval of Sofdra™ a pending prescription treatment for excessive underarm sweati...

ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could...

Imricor has two upcoming pivotal trials and is looking to transform cardiac ablation procedures  Botanix Pharmaceuticals is expecting US FDA approval for its lead dermatology product Sofdra in late June Bell Potter is confident in Paradigm...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

With a few notable exceptions, ASX cannabis shares widely underperformed again over the last year. That's a far cry from the heady days of 2019 and 2020 when ASX cannabis shares joined their American-listed peers in setting investors' portf...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy takes the position that the stock market’s recent winners will remain winners. Note that there is a big difference between mome...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Botanix Pharmaceuticals (ASX: BOT) Finishes its $13.5 million placement to accelerate its US commercial activities and to increase revenue turnaround The funds raised are for the commercial launch of Sofpironium Bromide gel, and the plac...

Two ASX cannabis shares aren't joining in the broader market rally today. During the Tuesday lunch hour, the All Ordinaries Index (ASX: XAO) is up 0.5%. But cannabis stocks Little Green Pharma Ltd (ASX: LGP) and Botanix Pharmaceuticals Lt...